Wang Bohan, Liu Yachong, Liao Zhibin, Wu Haofeng, Zhang Bixiang, Zhang Lei
Hepatic Surgery Center, Institute of Hubei Key Laboratory of Hepato-Pancreato-Biliary Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
Department of Hepatobiliary Surgery, Shanxi Tongji Hospital, Tongji Medical College, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Shanxi Medical University, Huazhong University of Science and Technology, Taiyuan, 030032, China.
Exp Hematol Oncol. 2023 Jun 2;12(1):52. doi: 10.1186/s40164-023-00405-2.
Hepatocellular carcinoma (HCC) is the leading cause of cancer-related death. The accumulation of genetic and epigenetic changes is closely related to the occurrence and development of HCC. Enhancer of zeste homolog 2 (EZH2, a histone methyltransferase) is suggested to be one of the principal factors that mediates oncogenesis by acting as a driver of epigenetic alternation. Recent studies show that EZH2 is widely involved in proliferation and metastasis of HCC cells. In this review, the functions of EZH2 in HCC progression, the role of EZH2 in tumor immunity and the application of EZH2-related inhibitors in HCC therapy are summarized.
肝细胞癌（HCC）是癌症相关死亡的主要原因。基因和表观遗传变化的积累与HCC的发生发展密切相关。zeste同源物2增强子（EZH2，一种组蛋白甲基转移酶）被认为是通过作为表观遗传改变的驱动因素介导肿瘤发生的主要因素之一。最近的研究表明，EZH2广泛参与HCC细胞的增殖和转移。在本综述中，总结了EZH2在HCC进展中的功能、EZH2在肿瘤免疫中的作用以及EZH2相关抑制剂在HCC治疗中的应用。
Zotero 插件